CyTOF and spectral flow cytometry are widely used technologies for high-dimensional single cell profiling of immune cells. Both technologies enable multiparameter single-cell analysis, but they differ significantly in how data are generated, how quickly studies can be executed, and how flexible an assay can be tailored for a specific program.
What is CyTOF and how does it work?
CyTOF, or mass cytometry, uses antibodies tagged with unique metal isotopes that are detected by time-of-flight mass spectrometry. Each marker is associated with a distinct heavy metal, resulting in minimal signal overlap and enabling very high parameter analysis. The labeled cells are nebulized, resulting in droplets which each contain a single cell that is eventually ionized. The ions are separated, detected, amplified and converted into electrical signals (Iyer et al., 2022).
What is spectral flow cytometry and how does it work?
Spectral flow cytometry uses fluorophore-tagged antibodies and captures the full emission spectrum of each fluorophore across multiple detectors. Computational unmixing algorithms separate signals based on their unique spectral signatures. Each signal corresponds to an antigen, either surface or intracellular, and can be analyzed together to evaluate the phenotype of individual cells. Importantly, live cells can be used in the assay, and in the case of cell sorting (conventional or spectral), live cells are retained after processing (Robinson et al., 2024).
Platform characteristics: CyTOF vs Spectral Flow Cytometry
| Category | CyTOF (mass cytometry) | Spectral flow cytometry |
| Strength | · Extremely high parameter capacity; up to 60 or more markers. · Minimal signal overlap simplifies panel design. |
· Supports high parameter panels (6-40+ colors) with improved unmixing over traditional flow. · High event acquisition speed. · Typically more accessible, widely supported, and lower operational cost than CyTOF. |
| Limitations | · Lower throughput compared to flow. · High instrument and reagent costs. · Lower sensitivity for very low-abundance markers. |
· Spectral spillover still exists and requires careful unmixing. · Panel design can be challenging due to fluorophore brightness and spectral similarity. · Performance depends heavily on optimized spectral reference libraries. |
| Time required to develop & validate a new method |
Longer development and validation time. · Panel design is simpler, but antibody‑metal conjugation, titration, batch‑to‑batch consistency, and stringent mass‑spec calibration extend timelines. · Method validation may require additional stability, carryover, and acquisition‑rate controls. |
Shorter development and validation time overall. · Although panel design is more complex, the workflow benefits from commercially pre-validated fluorophores, standardized unmixing controls, and familiar QC frameworks. · Validation can often be completed faster due to higher throughput and mature assay infrastructures. |
| Small projects | High minimum fees and limited reagent availability make small studies impractical and often force use of suboptimal panels. | Projects can be tailored to sponsor needs and scaled as programs grow. |
| Speed of data acquisition | Very slow acquisition, often 8-24 hours per run of 96 samples. | Fast acquisition, typically around 2-4 hours per 96 samples, depending on required event count. |
| Throughput | Low. Individual sample acquisition may take 5-15 minutes per sample. | High throughput, supporting large studies and rapid turnaround. |
| Sample constraints | Limited ability to accept whole blood. Large frozen batches experience long turnaround times. High rate of cell loss in processing. Typically requires higher cell input per sample, of at least 1 million cells. |
Flexible sample types, including whole blood and large frozen cohorts.
Starting cell input can be variable. 1 million cells is ideal, but when limited a few hundred thousand may be used. The starting input requirement is based on the frequency of the target population(s) of interest. |
| Dimensionality | Typically 40 to 60 or more markers. | Typically 30 to 40 markers with optimized panel design. |
| Cell viability | Cells are destroyed during acquisition. | Cells remain viable, enabling sorting and downstream assays. |
| Cost structure | High cost per sample. | More cost-efficient and scalable across study sizes. |
| Ideal use cases | · Deep immune profiling where maximal marker breadth is required. · Discovery‑stage immunology, oncology, and systems biology. · Situations where cell destruction is acceptable & high‑dimensional phenotyping is the priority. |
· High‑throughput immune profiling where speed and practicality matter. · Clinical or translational studies requiring reproducible, scalable assays. · Settings where rapid method development and validation are important. |
How we address key limitations of spectral flow cytometry
| Spectral flow limitation | How we address it | Example |
| Spectral spillover requiring careful unmixing | Panels are designed using fluorophores with minimal spectral similarity and validated with high-quality single-stain reference controls. | A 35-color immune panel maintained stable marker separation across multiple runs by optimizing fluorophore placement and unmixing controls. |
| Challenging panel design due to fluorophore brightness and similarity | Fluorophores are assigned based on antigen density, with the brightest dyes reserved for low-abundance targets. | Low-frequency activation markers were resolved consistently in whole blood by pairing them with high-brightness fluorophores. |
| Dependence on optimized spectral reference libraries | Standardized and lot-controlled reference libraries are maintained and refreshed as part of routine quality control. | Longitudinal studies preserved assay performance across time points by preparing reference controls at predefined intervals. |
Conclusion
CyTOF and spectral flow cytometry serve distinct needs in high-dimensional immune profiling. While CyTOF is well-suited for deep discovery requiring maximal marker breadth, spectral flow provides a more flexible, faster, and scalable solution. By addressing key technical limitations through optimized panel design and robust quality control, we enable spectral flow to deliver reliable, high-quality immune profiling that adapts as programs evolve.